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Abstract
Aim: To describe the feasibility of image guided intensity modulated radiotherapy (IG-IMRT) using daily soft tissue
matching in the treatment of bladder cancer.
Methods: Twenty-eight patients with muscle-invasive carcinoma of the bladder were recruited to a protocol of
definitive radiation using IMRT with accelerated hypofractionation with simultaneous integrated boost (SIB).
Isotropic margins of .5 and 1 cm were used to generate the high risk and intermediate risk planning target volumes
respectively. Cone beam CT (CBCT) was acquired daily and a soft tissue match was performed. Cystoscopy was
scheduled 6 weeks post treatment.
Results: The median age was 83 years (range 58-92). Twenty patients had stage II or III disease, and eight were
stage IV. Gross disease received 66 Gy in 30 fractions in 11 patients (ten with concurrent chemotherapy) or 55 Gy
in 20 fractions for those of poorer performance status or with palliative intent. All patients completed radiation
treatment as planned. Three patients ceased chemotherapy early due to toxicity. Six patients (21 %) had acute
Grade ≥ 2 genitourinary (GU) toxicity and six (21 %) had acute Grade ≥ 2 gastrointestinal (GI) toxicity. Five patients
(18 %) developed Grade ≥2 late GU toxicity and no ≥2 late GI toxicity was observed.
Nineteen patients underwent cystoscopy following radiation, with complete response (CR) in 16 cases (86 %),
including all patients treated with chemoradiotherapy. Eight patients relapsed, four of which were local relapses. Of
the patients with local recurrence, one underwent salvage cystectomy. For patients treated with definitive intent,
freedom from locoregional recurrence (FFLR) and overall survival (OS) was 90 %/100 % for chemoradiotherapy
versus 86 %/69 % for radiotherapy alone.
Conclusion: IG- IMRT using daily soft tissue matching is a feasible in the treatment of bladder cancer, enabling the
delivery of accelerated synchronous integrated boost with good early local control outcomes and low toxicity.
Introduction
Muscle Invasive bladder cancer presents a unique set of
treatment related challenges in what is typically an older
patient group with significant medical co-morbidity.
Radical surgery with cystectomy and pelvic lymph node
dissection poses many challenges in this group of
patients with high perioperative risks and potential
ongoing morbidity in relation to sexual dysfunction and
the physical and psychological impact of urinary diver-
sion [1–3]. Bladder preservation, in which radiation is
delivered with concurrent chemotherapy following
maximal trans-urethral resection of bladder tumour
(TURBT), is an alternative to surgical management, with
similar 5 year overall survival rates of 48-65 % account-
ing for stage and co-morbidity [4–6]. However it
remains underutilised, with patterns of care studies
showing that aggressive radiation-based treatment is
offered at a considerably lower rate compared with
cystectomy [7, 8].
One of the barriers to greater utilisation of radiother-
apy is perhaps the technical challenges with delivering
this treatment. The distortable nature of the bladder,
* Correspondence: Deborah.Whalley@health.nsw.gov.au
1Northern Sydney Cancer Centre, Radiation Oncology, Royal North Shore
Hospital, Reserve Road, St Leonards, Sydney, NSW 2065, Australia
Full list of author information is available at the end of the article
© 2015 Whalley et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Whalley et al. Radiation Oncology  (2015) 10:205 
DOI 10.1186/s13014-015-0499-0
variable bladder filling, as well as motion of other pelvic
organs all contribute to uncertainties with respect to
target coverage [9–11]. The use of image guidance and
adaptive therapy is potentially of great value in this
setting by allowing the reduction of planning target
volume (PTV) margins and improved target coverage
[10, 12–14]. Another challenge lies in the radiobiologic
characteristics of bladder cancer. There is a narrow
therapeutic window with respect to irradiation of the
bladder due to the risk of radiation toxicity to the blad-
der itself, as well as adjacent normal tissues [15, 16]. A
radiation dose response has been established in the
treatment of bladder cancer, but the wide margins
required for standard conformal techniques are dose
limiting [17, 18]. Furthermore, there is some evidence
that urothelial carcinoma displays sensitivity to overall
treatment time, with accelerated repopulation occurring
at 5-6 weeks after commencing radiation [19].
IMRT is of considerable interest in this regard due to
the superior conformality and normal tissue sparing
demonstrated with its use in other pelvic malignancies,
most notably prostate and cervical cancer [20, 21]. Its
application in bladder cancer is less frequently described,
but is appealing due to the potential to dose escalate
gross disease using an integrated boost technique, and
shorten overall treatment time. The concern with IMRT
is of geographic miss; however with daily on treatment
soft tissue alignment with CBCT it is possible to
overcome this obstacle. In 2010, the Northern Sydney
Cancer Centre developed a protocol of IG-IMRT with
daily soft tissue matching for the treatment of patients
with bladder cancer. Here, we report our experience




Approval for this study was obtained from the Northern
Sydney Local Health District Human Research Ethics
Committee. Potential candidates for the IG-IMRT proto-
col were identified at the genitourinary cancer multidiscip-
linary meeting attended by members of the departments
of Urology, Pathology, Radiology, Medical Oncology and
Radiation Oncology. Patients were eligible for treatment if
they had biopsy proven muscle-invasive urothelial or
squamous carcinoma of the bladder and were not for
definitive cystectomy (either due to inoperable disease or
patient preference). Exclusion criteria included previous
pelvic radiation, poor performance status (ECOG ≥3) and
extensive visceral metastases. Patients with low volume
metastases were considered if their life expectancy was
estimated to be >6 months.
In addition to diagnostic cystoscopy and biopsy,
patients underwent staging with whole body bone scan
and CT of the chest, abdomen and pelvis. Unless contra-
indicated, pelvic multiparametric MRI was performed to
aid tumour delineation. In patients being considered for
curative chemoradiation (CRT), maximal TURBT was
performed ≤6 weeks prior to commencing radiation
treatment. When possible, patients also had 3-4 gold
markers inserted near the tumour bed under cystoscopic
guidance. This procedure was performed by their Urolo-
gist under general anaesthesia.
Planning and treatment
After providing written consent for radiation treatment,
patients underwent CT simulation. Two image sets were
acquired for each patient: one with the patient’s bladder
comfortably full, and the second with an empty bladder.
Planning CT images were fused with the diagnostic
contrast-enhanced CT and MRI to aid tumour volume
delineation. As the bladder volume of the MRI com-
monly differed from the planning CT scan, the MRI was
interpreted with the aid of a radiologist to define the
anatomical area of the bladder at highest risk of gross
residual disease (GTV), which was then contoured. The
intermediate risk clinical target volume (IRCTV) was
defined as the whole bladder and expanded by 10 mm to
the intermediate risk PTV (IRPTV) and the GTV was
expanded by 0.5 cm to create the high risk PTV
(HRPTV). If treated, the uninvolved obturator, internal
and external iliac nodes were contoured as a separate
low risk CTV (LRCTV) and then expanded by a 1 cm
margin to a low risk PTV (LRPTV).
Most patients were subsequently treated with an
empty bladder, but the “full bladder” image set was used
in patients when appropriate to separate the small bowel
from the gross disease. This decision was made by the
treating oncologist before the planning was performed.
Radiation was planned and delivered using a 7-10 field
sliding-window IMRT technique on a Varian Trilogy
(Varian Medical Systems, Palo Alto, CA, USA). Patients
were treated with and accelerated moderate hypofractio-
nated schedule with either 20 or 30 fractions, incorpor-
ating a simultaneous integrated boost to the GTV if
identified. The 30 fraction group included patients with
localised disease who were regarded fit enough to re-
ceive combined chemo-irradiation. They received 66 Gy,
60 Gy and 54 Gy to the HRPTV, IRPTV and the pelvic
nodes respectively. In patients treated with 20 fractions,
the doses were 55 Gy, 50 Gy and 45 Gy without concur-
rent chemotherapy.
Platinum chemotherapy was administered concurrently
in suitable candidates. Chemotherapy was cisplatin
35 mg/m2 once weekly unless contraindicated when
weekly AUC2 carboplatin was used.
For patients planned with an empty bladder a hand-
held ultrasound was performed daily prior to treatment
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to ensure the bladder was empty. A CBCT was obtained
prior to treatment with the Varian Trilogy on board
imaging system with a 2.5 mm slice thickness over a
16 cm length with a resolution of 384 × 384 pixels.
Following this the treating radiation therapists per-
formed a soft tissue match to the GTV. This was super-
vised by the treating Radiation Oncologist for the first
five fractions, and thereafter as required based upon
feedback from the radiation therapist. The first step was
to identify if the bladder was outside the IRPTV, in
which case these patients were asked to further empty
their bladder. If present, fiducial markers were used to
aid initial alignment in the superior/inferior direction,
and then the GTV was matched. If no fiducials were
present then the GTV was used to guide the entire
match (see Fig. 1). This match was centred on the region
of the bladder identified as the highest risk of gross
disease (GTV), rather than identifying any abnormality
on the CBCT itself. In patients treated with a full blad-
der a margin of 10 mm above and below the superior
aspect of the bladder was defined on the planning scans.
Patients were required to have a bladder volume within
these limits on CBCT before proceeding with the match
to the GTV.
Assessment and follow up
Patients were assessed weekly during treatment and 3-6
monthly after treatment. Toxicity was graded by the
treating physician at each assessment according to the
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. Cystoscopy was performed 6-12
weeks post treatment and annually thereafter. CR was
defined as no visible evidence of bladder tumour and a
negative biopsy. The primary endpoint for the study was
freedom from local failure (FFLR). Secondary endpoints
were complete response rate on cystoscopy, acute and
late toxicity and overall survival.
Statistics
Survival outcomes were calculated from the first day of
radiation treatment to the first clinical, radiologic or
cystoscopic evidence of recurrence in the bladder
(FFLR), any recurrence (disease free survival, DFS) or
death (OS). In the absence of any of these events,
survival was censored at the last follow up. The rates of




Patient and tumour characteristics are outlined in
Table 1. In total, twenty-eight patients were treated on
this protocol between June 2010 and September 2013.
The cohort included 22 males and six females, with a
median age of 83 years (range 58-92). All but two
patients had muscle-invasive transitional cell carcinoma;
two others had squamous cell carcinoma. Stage T2, T3
and T4 disease was identified in 6, 14 and 8 patients
Fig. 1 GTV delineation and soft tissue match to GTV on CBCT. Figs. a and b demonstrate the following contours as delineated on MR fusion
(a) and planning CT (b): GTV – blue; High Risk PTV (HRPTV) – red; Bladder - pink; Intermediate Risk PTV (IRPTV) – purple and Low Risk PTV (LRPTV) –
light brown. Figs. c and d show these contours overlaid on the cone beam CT to facilitate soft tissue match
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respectively. Five patients had positive nodes, and four
patients had distant metastatic disease. A maximal
TURBT was possible in 64 % of cases and 32 % had
hydronephrosis at presentation. A further 36 % had a
history of previous superficial bladder cancer receiving
intravesical BCG.
Treatment and toxicity
Radiation and chemotherapy treatment details are out-
lined in Table 2. In 23 patients, radiation treatment was
given with curative intent with ten patients receiving
concurrent chemotherapy (cisplatin n = 8; carboplatin
n = 2) and 13 patients receiving radiation alone. In five
patients, who had either extensive nodal involvement
or metastatic disease at diagnosis, radiation treatment
was considered palliative. These patients received a
dose of 50-55 Gy in 20 fractions. A total of 22 patients
received treatment to the regional lymph nodes, includ-
ing all patients having concurrent chemotherapy. The
GTV was identified and treated with an integrated
boost in all but one patient. Fiducial markers were
successfully placed in nine patients. There were a total
of 680 fractions delivered to the 28 patients. Seventeen
patients were treated with an empty bladder and eleven
with a full bladder. Average treatment time, including
set-up was 11 min, with patients scheduled in standard
15-min bookings.
All patients completed radiation treatment as pre-
scribed. Reproducibility of bladder filling on the CBCT
was very good with an empty bladder, with only five of
400 fractions requiring patients to be removed from the
treatment couch. The full bladder protocol was less
reproducible, with seven of the 11 patients requiring at
least one re-set up to fill their bladders. In total, re-set
up was required for 29 of 280 fractions in the full
bladder group, 22 due to inadequate filling, five due to
overfilling, one due to machine breakdown and one due
to gas obscuring the GTV match. Of the 11 patients
who commenced treatment with a full bladder plan, two
were subsequently replanned with empty bladders, one
at fraction 5 and one at fraction 10.
Three patients ceased concurrent chemotherapy early,
two due to cisplatin-related emesis, and another due to
Grade 2 thrombocytopenia. Four patients required
admission to hospital during treatment. Two of these
admissions were for supportive care and intravenous
fluids due to treatment toxicity. A further two patients
were admitted overnight for packed-cell transfusion to
treat symptomatic anaemia resulting from haematuria
which had been present at baseline. In both cases, the
admissions took place in the first half of radiation treat-
ment and the haematuria subsequently resolved.
Acute Grade 2 GU toxicity was reported by six
patients (21 %). No patients experienced acute Grade 3
GU toxicity. Six patients reported Grade ≥2 GI toxicity,
including two patients with grade 3 nausea. There were
five patients (18 %) with Grade ≥2 late GU toxicity
including one patient requiring bilateral ureteric stents
(Grade 3). There was no late Grade 2 or 3 GI toxicity.
These figures are summarised in Table 3.
































Table 2 Treatment details
Treatment group (n)
All CRT Definitive RT Palliative RT
(n = 28) (n = 10) (n = 13) (n = 5)
20 fractions 17 0 12 5
30 fractions 11 10 1 0
GTV identified 27 10 12 5
LNs treated 22 10 9 3
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Outcomes
Patients were analysed according to the intent of treat-
ment (definitive versus palliative). Within the definitive
group, subset analyses were performed for patients
treated with chemoradiation and those who received
radiation alone. Results are summarised in Table 4.
Definitive cohort
Nineteen of the 23 definitive patients underwent cyst-
oscopy and biopsy following treatment, including nine
of the ten patients who received CRT and ten of 13
patients in the RT alone group. Of the four patients
who did not have cystoscopy, one was lost to follow
up overseas and three patients treated with RT alone
declined the procedure. The cystoscopic complete
response rate was 86 %, (100 % in the CRT group
and 81 % in the radiotherapy alone group). At 2 years
the local control was 90 % in the CRT group and
86 % in the definitive RT alone group and OS was
100 % and 69 % respectively.
In patients treated definitively, freedom from local
failure was 78 % at 2 years (Fig. 2). There were four local
failures, with one patient proceeding to salvage cystec-
tomy. Of the remaining three patients, two declined
intervention and remain alive with disease; one patient
has died as a result of obstructive renal failure. A further
two patients in the group have had documented distant
relapse. The DFS and overall survival rates were 73 %
and 80 % at 2 years respectively. Kaplan Meier curves
for overall survival are shown in Fig. 3.
Palliative cohort
Three of the five patients treated with palliative intent
died during the follow up period, two due to bladder
cancer and one from an unrelated illness. One patient
experienced local progression, translating to a 1 year
FFLR of 80 %, and a median of 6 months. Median
survival was 10 months (1 year OS 30 %).
Discussion
In our series, IG-IMRT with a synchronous integrated
boost was well tolerated, with excellent early results.
Although longer follow up is required, the high complete
response rate and 2 year loco-regional control support
the feasibility and promise of this technique.
The heterogeneous nature of our cohort in terms of
tumour stage and treatment is acknowledged. However,
allowing for this, our results compare favourably to
larger bladder preservation studies employing 3D con-
formal techniques and minimal image guidance. In the
landmark BC2001 study of chemoradiation with mito-
mycin and 5-fluorouracil versus radiation alone, James
et al. reported a 2-year locoregional DFS of 67 % in
the chemoradiotherapy group, and 54 % in the radio-
therapy alone group [5]. In two sequential phase II
trials of definitive chemoradiation with weekly low
dose cisplatin conducted by the Trans Tasman Radi-
ation Oncology Group (TROG) Gogna et al. reported
a CR rate of 70 % and local control of 45 % at 5 years
[22]. This compares to our cohort who had a 90 %
2 year local control following chemoradiotherapy and
86 % for radiotherapy alone.
Although there is limited literature on the use of
IMRT for bladder cancer, two studies that are available
report similar outcomes. Turgeon et al. reported a CR
rate of 83 % and a 2 year OS of 69 % in a series of 24
patients treated with hypofractionated IMRT and con-
current chemotherapy [23]. In a separate prospective
study Hsieh et al. described a 2-year locoregional recur-
rence free survival of 87.5 % in 19 patients with bladder
cancer who were treated with either IMRT or tomother-
apy. The overall survival in their cohort was low (26.3 %
at 2 years) reflecting the fact that one third of the cohort
had stage IV disease [24]. Of note neither of these
studies used daily soft tissue matching, and PTV
margins were generous at 1.5 to 2.5 cm. The addition of
daily soft tissue matching in our protocol allowed a
margin reduction to 0.5 cm for high-risk areas and 1 cm
around the bladder. With the use of IMRT and small
Table 3 Genitourinary (GU) and Gastrointestinal (GI) treatment
toxicity
Worst CTCAE grade, any event (n)
0 1 2 3
Acute toxicity
- GU 4 18 6 0
- GI 8 14 4 2
Late toxicity
- GU 10 13 4 1
- GI 17 11 0 0
n number of patients, CTCAE Common Terminology Criteria for Adverse Events
Table 4 Outcomes according to treatment group
Treatment group n(%)
Total CRT Definitive RT Palliative
Cystoscopy 22 9 10 3
CRa 19 (86) 9 (100) 8 (80) 2 (60)
Failure 8 0 5 3
- Local 4 1 2 1
- Distant 3 0 1 2
- Local and distant 1 0 1 0
Death 8 0 5 3
- From bladder cancer 5 0 3 2
- From other cause 3 0 2 1
aCR = % of patients who underwent cystoscopy and had a complete response
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Fig. 2 Kaplan Meier curve of Freedom from Locoregional Recurrence (FFLR) for definitive and palliative patients
Fig. 3 Overall survival for definitive and palliative patients
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margins, relative dose escalation was possible while
achieving low toxicity (see Table 3).
Palliative cases notwithstanding, our cohort as a whole
represents a high-risk population. The majority of the
cases were stage III/IV, and overall the patients were
elderly (median age 83 years). One third of patients had
hydronephrosis, incomplete TURBT or a history of
superficial carcinoma progressing despite BCG, all of
which are known poor prognostic indicators [25–28]. In
this context, our 2 year FFLR and OS for the defini-
tive cohort (78 % and 80 % respectively) are very en-
couraging. Therefore although we have demonstrated
excellent outcomes for a highly selected group of patients
who received combined chemoradiation, high dose radi-
ation need not be reserved for these patients alone.
The acute toxicity observed in our cohort was modest
compared to rates reported in other high dose trials.
James et al. reported CTCAE grade 3-4 acute side effects
in 27.5 % and 36 % in the radiotherapy alone and
chemoradiotherapy groups respectively [5]. In the TROG
chemoradiation trials, 35 % of patients experienced
grade 2 GI effects, and more than 40 % reported grade 2
GU toxicity [22]. These trials used conformal radiation
techniques, and we note that the low GI toxicity experi-
enced by our patients is in keeping with the normal
tissue sparing properties of pelvic IMRT [23, 24]. More
specifically, clinical and planning studies have demon-
strated the superiority of IMRT compared with con-
formal therapy with respect to small bowel volumes
receiving doses of 20-50Gy [29, 30]. This is of particular
relevance to patients in whom the clinical target extends
beyond the bladder to include the regional nodes, as was
the case in the majority of our patients. Although pelvic
nodal relapse following bladder radiotherapy is report-
edly uncommon, the large margins employed for the
radiation delivered in previous trials may have resulted
in the majority of the regional nodes receiving thera-
peutic radiation doses. In our cohort, nodal irradiation
was justified on the basis of the comparatively small
margins (1 cm) used in our technique and evidence from
surgical series demonstrating improved outcome with
nodal dissection [31].
Our patients received a simultaneous integrated boost
to the GTV, identified using clinical, cystoscopic and
radiologic information. We found multiparametric MRI
to be a substantial aid in GTV delineation. The main
limitation with MRI fusion was the requirement for a
comfortably full bladder at the time of MRI to aid diag-
nostic reporting, with most patients having their final
volumes on an empty bladder scan. We are currently
investigating elastic deformation to account for the
anisotropic margins required for changes in bladder size,
which will enable better fusion of the MRI and planning
CT. MRI is not only promising with respect to bladder
tumour staging and characterisation, but also as a potential
predictor of pathologic response to therapy [32, 33].
An alternative means to identify the GTV is fiducial
markers, which were successfully placed around the
tumour bed in nine of our patients. Elsewhere, the use
of fiducial markers has been reported with few complica-
tions and excellent visibility on CBCT [34–36]. However,
in our experience, the implementation of a fiducial
marker program for bladder radiation proved to be a
challenging process and did not always aid in tumour
delineation. As such it was ceased part way through the
study. Custom-designed equipment as described by
Garcia et al. may address some of the technical difficul-
ties that inhibited marker placement in many of our
patients [34].
Various adaptive strategies have been described by
several groups including ‘PTV of the day’ selection,
isocentre shifts and corrections for translational and
rotational motion [12, 14, 37, 38]. Our daily image-
guidance with CBCT and soft tissue match is unique
with no previously published IMRT series utilising this
approach. It is clear from the extensive experience in
other pelvic malignancies that as the quality of on-board
CBCT imaging has improved, so has the workflow and
ease of matching. In our patients, on average treatment
was completed well within the allocated time, and there-
fore did not impact adversely on departmental resources
or workflow. The treating Radiation Oncologist super-
vised the matching during the first week of treatment
and only attended subsequent to this if problems were
identified by the radiation therapy team, including the
seven occasions when reset up was required and two
patients who ultimately needed replanning.
In a paper comparing matching techniques in patients
treated on an adaptive planning bladder study, Foroudi
et al. found 1 cm CTV to PTV margins were found to
be feasible when using soft tissue match. The resulting
coverage with this margin was adequate in 89 % of cases,
whereas margins of 2 cm or greater were required to
achieve the same coverage using bony alignment or skin
tattoos [39]. Our study further supports this finding,
with only 5/400 fractions treated with an empty bladder
requiring the patient to be taken off the table. We
believe this high rate of daily bladder filling reproducibil-
ity is a result of patient education with respect to
bladder emptying and subsequent reinforcement by daily
feedback from the treating therapists based on ultra-
sound and CBCT images. This is in contrast to the large
variations in bladder filling reported from the recent
TROG study: 16 % of patients in that study had, on at least
one occasion, a pre-treatment bladder CTV extending
beyond all of the three possible adaptive plans [37].
A limitation of our study was no CBCTs were
performed after treatment to assess intrafraction motion
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which may be important, especially with the high dose
gradients of IMRT which could be more pronounced on
days of hydration for cisplatin chemotherapy [37]. The
risk is the bladder may move outside the IRPTV for part
of the beam-on time. Our excellent local control, despite
this risk, supports the concept that not all regions of the
bladder require the same dose. This was shown in the
BC2001 study. In this study there was similar 2-year
local control with partial bladder irradiation (64 %) and
full bladder irradiation (61 %) [40]. Intrafraction motion
will also be reduced in the future with the introduction
of volumetric arc therapy (VMAT) [41].
Conclusion
IG-IMRT with daily soft tissue matching is a promis-
ing approach in the treatment of muscle invasive
bladder cancer, enabling the delivery of an accelerated
simultaneous integrated boost IMRT with low rates of
toxicity. Early local control and disease free survival
are encouraging, especially in light of our high-risk
population. Longer follow-up is required to assess the
efficacy of this technique.
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